NTN4

Across TCGA pan-cancer cohorts, NTN4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NTN4 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NTN4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NTN4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, OV, and UCEC are the cancer types where NTN4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.136	0.657	<.001	27	view →
OV	OS	Median	II,III,IV	0.323	0.843	.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.022	18	view →
GBM	OS	Median	All	0.020	0.416	<.001	12	view →
SARC	OS	Median	All	0.241	0.766	.022	6	view →
ACC	DFS	Median	II,III,IV	0.242	0.724	.034	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NTN4–BLCA (OS)

Open the BLCA breakdown →